Sign In
Buy RLMD
$6.33
-0.0900 (-1.40%)
At Close: Jun 03, 2026
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
04:10pm, Wednesday, 12'th May 2021
NEW YORK, May 12, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate
Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021
04:30pm, Thursday, 06'th May 2021
NEW YORK, May 6, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it wi
Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021
08:30am, Saturday, 01'st May 2021
NEW YORK, May 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clini
Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting
08:30am, Thursday, 29'th Apr 2021
NEW YORK, April 29, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that da
NEW YORK, April 27, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that da
NEW YORK, April 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the initi
Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q4 2020 Results - Earnings Call Transcript
01:41am, Wednesday, 24'th Mar 2021
Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q4 2020 Results - Earnings Call Transcript
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
04:23pm, Tuesday, 23'rd Mar 2021
NEW YORK, March 23, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corpora
NEW YORK, March 18, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it
Relmada Therapeutics Announces Participation in the Oppenheimer 31st Annual Healthcare Conference
08:30am, Thursday, 11'th Mar 2021
NEW YORK, March 11, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that S
Is the Options Market Predicting a Spike in Relmada (RLMD) Stock?
09:47am, Wednesday, 23'rd Dec 2020
Investors need to pay close attention to Relmada (RLMD) stock based on the movements in the options market lately.
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that the f
